[go: up one dir, main page]

MA27247A1 - Utilisation combinee de derive indolopyrrolocarbazole antitumoral et autre agent antitumoral - Google Patents

Utilisation combinee de derive indolopyrrolocarbazole antitumoral et autre agent antitumoral

Info

Publication number
MA27247A1
MA27247A1 MA27853A MA27853A MA27247A1 MA 27247 A1 MA27247 A1 MA 27247A1 MA 27853 A MA27853 A MA 27853A MA 27853 A MA27853 A MA 27853A MA 27247 A1 MA27247 A1 MA 27247A1
Authority
MA
Morocco
Prior art keywords
tumor
pharmaceutically acceptable
antitumor
preparation
combined
Prior art date
Application number
MA27853A
Other languages
English (en)
Inventor
Hiroharu Arakawa
Yoko Nakatsuru
Yoshiaki Monden
Tsutomu Kodera
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MA27247A1 publication Critical patent/MA27247A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à une préparation combinée pour administration simultanée, séparée ou séquentielle dans le traitement du cancer, comprenant deux préparations séparées: * une préparation comprenant, en combinaison avec un support ou diluant pharmaceutiquement acceptable, au moins un composé de la formule générale I : dans laquelle R1 et R2 représentent chacun indépendamment un atome d'hydrogène, alkyle inférieur, ou du même genre, et G représente un pentosyle ou du même genre, X1 et X2 représentent chacun indépendamment un atome d'hydrogène, un atome d'halogène, ou du même genre ou un de leurs sels pharmaceutiquement acceptables; et * une préparation, en combinaison avec un support ou diluant pharmaceutiquement acceptable, telle que des agents alcoylants antitumoraux, des antimétabolites antitumoraux, des antibiotiques antitumoraux, ou des agents antitumoraux issus de végétaux (une préparation comprenant au moins un composé de la formule générale I ou un de ses sels pharmaceutiquement acceptables peut être combinée avec deux ou plusieurs autres agents antitumoraux), et une méthode pour le traitement du cancer comprenant l'administration de ces préparations combinées.
MA27853A 2002-03-26 2004-09-10 Utilisation combinee de derive indolopyrrolocarbazole antitumoral et autre agent antitumoral MA27247A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002084677 2002-03-26

Publications (1)

Publication Number Publication Date
MA27247A1 true MA27247A1 (fr) 2005-03-01

Family

ID=28449220

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27853A MA27247A1 (fr) 2002-03-26 2004-09-10 Utilisation combinee de derive indolopyrrolocarbazole antitumoral et autre agent antitumoral

Country Status (25)

Country Link
US (1) US20050171036A1 (fr)
EP (1) EP1498127A4 (fr)
JP (1) JPWO2003080077A1 (fr)
KR (1) KR20040097237A (fr)
CN (1) CN100490817C (fr)
AP (1) AP2004003120A0 (fr)
AU (1) AU2002335472B8 (fr)
BR (1) BR0215650A (fr)
CA (1) CA2480335A1 (fr)
CO (1) CO5611155A2 (fr)
EA (1) EA008302B1 (fr)
EC (1) ECSP045301A (fr)
IL (1) IL164193A0 (fr)
IS (1) IS7379A (fr)
MA (1) MA27247A1 (fr)
MX (1) MXPA04009324A (fr)
NO (1) NO20044030L (fr)
NZ (1) NZ534914A (fr)
OA (1) OA12794A (fr)
PL (1) PL370866A1 (fr)
RS (1) RS84904A (fr)
TN (1) TNSN04185A1 (fr)
UA (1) UA80552C2 (fr)
WO (1) WO2003080077A1 (fr)
ZA (1) ZA200406716B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20014256D0 (no) 2001-09-03 2001-09-03 Bjoern Kristiansen Fremstilling av immunstimulerende forbindelse
KR101064901B1 (ko) * 2003-03-20 2011-09-16 나노캐리어 가부시키가이샤 난수용성 항암제와 신규 블록 공중합체를 포함하는 미셀조제물
US7514085B2 (en) 2004-07-16 2009-04-07 Medimush A/S Immune modulating compounds from fungi
JP4820758B2 (ja) * 2004-09-22 2011-11-24 日本化薬株式会社 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤
KR100968818B1 (ko) * 2004-12-03 2010-07-08 현대자동차주식회사 차량용 리어 쇽업쇼버의 보호 커버 구조
US20110182909A1 (en) * 2004-12-23 2011-07-28 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
CN100358482C (zh) * 2005-01-31 2008-01-02 武汉理工大学 多功能医用金属支架及制备方法
CN100431607C (zh) * 2005-02-03 2008-11-12 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
US9072776B2 (en) 2005-06-15 2015-07-07 Glycanova As Anti-cancer combination treatment and kit-of-parts
NZ587586A (en) * 2005-07-18 2012-04-27 Bipar Sciences Inc Treatment of cancer
RU2447095C2 (ru) * 2006-05-18 2012-04-10 Ниппон Каяку Кабусики Кайся Высокомолекулярный конъюгат подофиллотоксинов
WO2008030883A2 (fr) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Traitement du cancer
WO2008030891A2 (fr) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition de la synthèse d'acides gras au moyen d'inhibiteurs parp et méthodes de traitement associées
US20090239782A1 (en) * 2006-10-03 2009-09-24 Masaharu Nakamura High-molecular weight conjugate of resorcinol derivatives
CN100571709C (zh) * 2007-06-01 2009-12-23 中国医学科学院医药生物技术研究所 一种有抗肿瘤协同增效作用的药物组合物
WO2009041570A1 (fr) 2007-09-28 2009-04-02 Nippon Kayaku Kabushiki Kaisha Conjugué polymère-stéroïde
CN101903025A (zh) * 2007-10-19 2010-12-01 彼帕科学公司 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
NZ586125A (en) 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
ES2402138T3 (es) * 2007-12-28 2013-04-29 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Terapia contra el cáncer con un parvovirus combinado con quimioterapia
CN101977631A (zh) * 2008-03-18 2011-02-16 日本化药株式会社 生理活性物质的高分子量偶联物
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
WO2010131675A1 (fr) 2009-05-15 2010-11-18 日本化薬株式会社 Conjugue polymere de substance bioactive comprenant un groupe hydroxy
CN102198150B (zh) * 2010-03-26 2013-11-06 中国医学科学院医药生物技术研究所 双活性成分抗肿瘤药物及其应用
US9018323B2 (en) 2010-11-17 2015-04-28 Nippon Kayaku Kabushiki Kaisha Polymer derivative of cytidine metabolic antagonist
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
RU2623426C2 (ru) 2011-09-11 2017-06-26 Ниппон Каяку Кабусики Кайся Способ получения блок-сополимера
CN117486782A (zh) * 2023-12-29 2024-02-02 中国医学科学院药用植物研究所 一种n-取代咔唑衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589365A (en) * 1991-11-29 1996-12-31 Banyu Pharmaceutical Co., Ltd. Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
PL172316B1 (en) * 1991-11-29 1997-09-30 Banyu Pharma Co Ltd Method of obtaining novel derivatives of indolopyrrole carbazole
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
CN1035878C (zh) * 1992-02-18 1997-09-17 万有制药株式会社 吲哚并吡咯并咔唑衍生物
US5922860A (en) * 1994-05-09 1999-07-13 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazole derivatives
JP3536574B2 (ja) 1997-02-28 2004-06-14 萬有製薬株式会社 抗腫瘍性インドロピロロカルバゾール誘導体
FR2772763B1 (fr) * 1997-12-24 2004-01-23 Sod Conseils Rech Applic Nouveaux analogues tetracycliques de camptothecines, leurs procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
ATE322266T1 (de) * 2000-05-15 2006-04-15 Celgene Corp Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten

Also Published As

Publication number Publication date
WO2003080077A1 (fr) 2003-10-02
OA12794A (en) 2006-07-10
KR20040097237A (ko) 2004-11-17
ECSP045301A (es) 2004-11-26
EP1498127A4 (fr) 2008-02-06
NZ534914A (en) 2007-01-26
AU2002335472B8 (en) 2007-12-20
CA2480335A1 (fr) 2003-10-02
MXPA04009324A (es) 2005-01-25
PL370866A1 (en) 2005-05-30
IL164193A0 (en) 2005-12-18
CO5611155A2 (es) 2006-02-28
IS7379A (is) 2004-07-29
AU2002335472B2 (en) 2007-12-13
AU2002335472A1 (en) 2003-10-08
NO20044030L (no) 2004-12-16
UA80552C2 (en) 2007-10-10
JPWO2003080077A1 (ja) 2005-07-21
TNSN04185A1 (en) 2007-03-12
EA200401254A1 (ru) 2005-02-24
US20050171036A1 (en) 2005-08-04
BR0215650A (pt) 2005-01-04
RS84904A (sr) 2006-12-15
EA008302B1 (ru) 2007-04-27
CN100490817C (zh) 2009-05-27
ZA200406716B (en) 2006-07-26
AP2004003120A0 (en) 2004-09-30
CN1622814A (zh) 2005-06-01
EP1498127A1 (fr) 2005-01-19

Similar Documents

Publication Publication Date Title
MA27247A1 (fr) Utilisation combinee de derive indolopyrrolocarbazole antitumoral et autre agent antitumoral
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA30428B1 (fr) Derives de dihydropyrazolopyrimidinones
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA26952A1 (fr) Derives d'imidazole a noyau aryle ou heteroaryle condense, utiles comme agents anti-inflammatoires et analgesiques.
GEP20033000B (en) 2-Substituted-1-Piperidyl Benzimidazole Compounds as ORL1-Receptor Agonists
MA28747B1 (fr) Dérivés de pyridine
CA2367017A1 (fr) Inhibiteurs de l'enzyme impdh
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
TW200619199A (en) 3-carbamoyl-2-pyridone derivatives
CA2662848C (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-.alpha.]pyridines, leur preparation et leur application en therapeutique
MA30075B1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MA29968B1 (fr) Compose cinnamide bicyclique
TN2010000248A1 (fr) Derives d'indolinone et procede pour leur fabrication
TNSN07275A1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA29775B1 (fr) Derives de pyrazolone
MA30719B1 (fr) Nouveaux derives d'aminopyridine ayant une action inhibitrice selective sur aurora a.
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
MA57000B1 (fr) Dérivés d'alpha-d-galactopyranoside
MA27747A1 (fr) Dérivés azabicycliques à substituants pyridyloxyméthyle et benzisoxazole
CA2246485A1 (fr) Nouveaux derives de l'indole et de l'indazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA27066A1 (fr) 6,7-DIHYDRO-5H-PYRAZOLO[1,2-A]PYRAZOL-1-ONES CONTRôLANT LES CYTOKINES INFLAMMATOIRES.
MXPA04008303A (es) Inhibidores de la farnesil proteina transferasa como agentes antitumorales.
CA2326710A1 (fr) Nouveaux derives de dihydrofuro-¬3,4-b|quinolein-1-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent